Differential type I interferon signaling is a master regulator of susceptibility to postinfluenza bacterial superinfection

mBio

Volumn 7, Issue 3, 2016, Pages

  Shepardson, Kelly M ^a   Larson, Kyle ^a   Morton, Rachelle V ^a   Prigge, Justin R ^a   Schmidt, Edward E ^a   Huber, Victor C ^b   Rynda Apple, Agnieszka ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GLYCOPROTEIN P 15095; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 13; ALPHA BETA INTERFERON RECEPTOR; LY ANTIGEN; LY6G ANTIGEN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL SUPERINFECTION; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOCOMPETENT CELL; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPLICATION; DISEASE PREDISPOSITION; HUMAN; IMMUNOLOGY; INFLUENZA; KNOCKOUT MOUSE; LEUKOCYTE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERINFECTION;

ANIMALS; ANTIGENS, CD11C; ANTIGENS, LY; DISEASE SUSCEPTIBILITY; HUMANS; INFLUENZA, HUMAN; INTERFERON TYPE I; INTERLEUKIN-13; LEUKOCYTES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAPHYLOCOCCAL INFECTIONS; SUPERINFECTION;

EID: 84979031938     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00506-16     Document Type: Article

References (67)

1. Metersky ML, Masterton RG, Lode H, File TM, Babinchak T. 2012. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 16: e321-e331. http://dx.doi.org/10.1016/j.ijid.2012.01.003.
2. McCullers JA. 2014. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12: 252-262. http://dx.doi.org/10.1038/nrmicro3231.
3. Chertow DS, Memoli MJ. 2013. Bacterial coinfection in influenza A grand rounds review. JAMA 309: 275-282. http://dx.doi.org/10.1001/jama.2012.194139.
4. Lee M-H, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD. 2010. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 201: 508-515. http://dx.doi.org/10.1086/650204.
5. Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA. 2011. Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis 203: 880-888. http://dx.doi.org/10.1093/infdis/jiq113.
6. Brundage JF. 2006. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 6: 303-312. http://dx.doi.org/10.1016/S1473-3099(06)70466-2.
7. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, Belperio JA, Cheng G, Deng JC. 2009. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119: 1910-1920. http://dx.doi.org/10.1172/JCI35412.
8. Rynda-Apple A, Harmsen A, Erickson AS, Larson K, Morton RV, Richert LE, Harmsen AG. 2014. Regulation of IFN-+ by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. Eur J Immunol 44: 3263-3272. http://dx.doi.org/10.1002/eji.201444582.
9. Sun K, MetzgerDW. 2008. Inhibition of pulmonary antibacterial defense by interferon-+ during recovery from influenza infection. Nat Med 14: 558-564. http://dx.doi.org/10.1038/nm1765.
10. Decker T, Müller M, Stockinger S. 2005. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5: 675-687. http://dx.doi.org/10.1038/nri1684.
11. Van Boxel-Dezaire AH, Rani MR, Stark GR. 2006. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25: 361-372. http://dx.doi.org/10.1016/j.immuni.2006.08.014.
12. Trinchieri G. 2010. Type I interferon: friend or foe? J Exp Med 207: 2053-2063. http://dx.doi.org/10.1084/jem.20101664.
13. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384. http://dx.doi.org/10.1038/ni.1863.
14. Yoneyama M, Fujita T. 2009. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 227: 54-65. http://dx.doi.org/10.1111/j.1600-065X.2008.00727.x.
15. Okahira S, Nishikawa F, Nishikawa S, Akazawa T, Seya T, Matsumoto M. 2005. Interferon-beta induction through Toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol 24: 614-623. http://dx.doi.org/10.1089/dna.2005.24.614.
16. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF. 2003. Cross-priming of CD8_T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015. http://dx.doi.org/10.1038/ni978.
17. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei X-Q, Liew FY, Caligiuri MA, Durbin JE, Biron CA. 2002. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169: 4279-4287. http://dx.doi.org/10.4049/jimmunol.169.8.4279.
18. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650. http://dx.doi.org/10.1084/jem.20050821.
19. Gil MP, Ploquin MJ, Watford WT, Lee S-H, Kim K, Wang X, Kanno Y, O’Shea JJ, Biron CA. 2012. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood 120: 3718-3728. http://dx.doi.org/10.1182/blood-2012-05-428672.
20. Meissner N, Swain S, McInnerney K, Han S, Harmsen AG. 2010. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. Am J Pathol 176: 2806-2818. http://dx.doi.org/10.2353/ajpath.2010.091158.
21. Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P. 2007. Protective role of beta interferon in host defense against influenza A virus. J Virol 81: 2025-2030. http://dx.doi.org/10.1128/JVI.01718-06.
22. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, Matsuoka Y, Sambhara S, Swayne DE, Tumpey TM, Katz JM. 2009. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 83: 5825-5834. http://dx.doi.org/10.1128/JVI.02144-08.
23. Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T, Yoshikai Y. 2013. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res 99: 230-237. http://dx.doi.org/10.1016/j.antiviral.2013.05.007.
24. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, Fasano A, Vogel SN. 2010. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol 3: 29-39. http://dx.doi.org/10.1038/mi.2009.120.
25. Parker D, Planet PJ, Soong G, Narechania A, Prince A. 2014. Induction of type I interferon signaling determines the relative pathogenicity of Staphylococcus aureus strains. PLoS Pathog 10: e1003951. http://dx.doi.org/10.1371/journal.ppat.1003951.
26. Martin FJ, Gomez MI, Wetzel DM, Memmi G, O’Seaghdha M, Soong G, Schindler C, Prince A. 2009. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest 119: 1931-1939. http://dx.doi.org/10.1172/JCI35879.
27. Parker D, Prince A. 2012. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 189: 4040-4046. http://dx.doi.org/10.4049/jimmunol.1201055.
28. Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, Deng JC. 2012. Poly I: C enhances susceptibility to secondary pulmonary infections by Gram-positive Bacteria. PLoS One 7: e41879. http://dx.doi.org/10.1371/journal.pone.0041879.
29. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow RI, Kolls JK, Alcorn JF. 2011. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 186: 1666-1674. h t t p: //d x. d o i. o r g /1 0. 4 0 4 9 /jimmunol.1002194.
30. Li W, Moltedo B, Moran TM. 2012. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of _+ T cells. J Virol 86: 12304-12312. http://dx.doi.org/10.1128/JVI.01269-12.
31. Lee B, Robinson KM, McHugh KJ, Scheller EV, Mandalapu S, Chen C, Di YP, Clay ME, Enelow RI, Dubin PJ, Alcorn JF. 2015. Influenzainduced type I interferon enhances susceptibility to Gram-negative and Gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 309: L158-L167. http://dx.doi.org/10.1152/ajplung.00338.2014.
32. Goritzka M, Makris S, Kausar F, Durant LR, Pereira C, Kumagai Y, Culley FJ, Mack M, Akira S, Johansson C. 2015. Alveolar macrophagederived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med 212: 699-714. http://dx.doi.org/10.1084/jem.20140825.
33. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. 2013. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse Lung. Am J Respir Cell Mol Biol 49: 503-510. http://dx.doi.org/10.1165/rcmb.2013-0086MA.
34. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174: 4465-4469. http://dx.doi.org/10.4049/jimmunol.174.8.4465.
35. Carrero JA, Calderon B, Unanue ER. 2004. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 200: 535-540. http://dx.doi.org/10.1084/jem.20040769.
36. Schreiber G, Piehler J. 2015. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol 36: 139-149. http://dx.doi.org/10.1016/j.it.2015.01.002.
37. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G. 2011. Binding and activity of all human alpha interferon subtypes. Cytokine 56: 282-289. http://dx.doi.org/10.1016/j.cyto.2011.07.019.
38. Jaks E, Gavutis M, Uzé G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525-539. http://dx.doi.org/10.1016/j.jmb.2006.11.053.
39. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Saïd-Salim B, Porcella SF, Long RD, Dorward DW, Gardner DJ, Kreiswirth BN, Musser JM, DeLeo FR. 2005. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 175: 3907-3919. http://dx.doi.org/10.4049/jimmunol.175.6.3907.
40. Chen WH, Toapanta FR, Shirey KA, Zhang L, Giannelou A, Page C, Frieman MB, Vogel SN, Cross AS. 2012. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol Lett 141: 227-234. http://dx.doi.org/10.1016/j.imlet.2011.10.009.
41. Sun K, Metzger DW. 2014. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 192: 3301-3307. http://dx.doi.org/10.4049/jimmunol.1303049.
42. De Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053-20057. http://dx.doi.org/10.1074/jbc.R700006200.
43. Colonna M, Trinchieri G, Liu Y-J. 2004. Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226. http://dx.doi.org/10.1038/ni1141.
44. Wolf AI, Buehler D, Hensley SE, Cavanagh LL, Wherry EJ, Kastner P, Chan S, Weninger W. 2009. Plasmacytoid dendritic cells are dispensable during primary influenza virus infection. J Immunol 182: 871-879. http://dx.doi.org/10.4049/jimmunol.182.2.871.
45. Parker D, Prince A. 2011. Type I interferon response to extracellular bacteria in the airway epithelium. Trends Immunol 32: 582-588. http://dx.doi.org/10.1016/j.it.2011.09.003.
46. Rynda-Apple A, Dobrinen E, McAlpine M, Read A, Harmsen A, Richert LE, Calverley M, Pallister K, Voyich J, Wiley JA, Johnson B, Young M, Douglas T, Harmsen AG. 2012. Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function. AmJ Pathol 181: 196-210. http://dx.doi.org/10.1016/j.ajpath.2012.03.018.
47. Taniguchi T, Takaoka A. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2: 378-386. http://dx.doi.org/10.1038/35073080.
48. Deonarain R, Chan DC, Platanias LC, Fish EN. 2002. Interferon-alpha/beta-receptor interactions: a complex story unfolding. Curr Pharm Des 8: 2131-2137.
49. Porritt RA, Hertzog PJ. 2015. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol 36: 150-160. http://dx.doi.org/10.1016/j.it.2015.02.002.
50. Levin D, Schneider WM, Hoffmann H-H, Yarden G, Busetto AG, Manor O, Sharma N, Rice CM, Schreiber G. 2014. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci Signal 7: ra50. http://dx.doi.org/10.1126/scisignal.2004998.
51. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of Type I interferon signaling. Science 340: 207-211. http://dx.doi.org/10.1126/science.1235214.
52. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207. http://dx.doi.org/10.1126/science.1235208.
53. De Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff S-J, Zaker-Tabrizi L, Fung KY, Forster SC, Beddoe T, Reid HH, Rossjohn J, Hertzog PJ. 2013. Structural basis of a unique interferon-+ signaling axis mediated via the receptor IFNAR1. Nat Immunol 14: 901-907. http://dx.doi.org/10.1038/ni.2667.
54. Williams AE, Edwards L, Hussell T. 2006. Colonic bacterial infection abrogates eosinophilic pulmonary disease. J Infect Dis 193: 223-230. http://dx.doi.org/10.1086/498915.
55. Robinson KM, McHugh KJ, Mandalapu S, Clay ME, Lee B, Scheller EV, Enelow RI, Chan YR, Kolls JK, Alcorn JF. 2014. Influenza A virus exacerbates Staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J Infect Dis 209: 865-875. http://dx.doi.org/10.1093/infdis/jit527.
56. Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK, Alcorn JF. 2013. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice. J Immunol 191: 5153-5159. http://dx.doi.org/10.4049/jimmunol.1301237.
57. Wan L, Lin C-W, Lin Y-J, Sheu JJ, Chen B-H, Liao C-C, Tsai Y, Lin W-Y, Lai C-H, Tsai FJ. 2008. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med 12: 876-888. http://dx.doi.org/10.1111/j.1582-4934.2008.00143.x.
58. Chen H, Sun H, You F, Sun W, Zhou X, Chen L, Yang J, Wang Y, Tang H, Guan Y, Xia W, Gu J, Ishikawa H, Gutman D, Barber G, Qin Z, Jiang Z. 2011. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147: 436-446. http://dx.doi.org/10.1016/j.cell.2011.09.022.
59. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 461: 788-792. http://dx.doi.org/10.1038/nature08476.
60. Prigge JR, Hoyt TR, Dobrinen E, Capecchi MR, Schmidt EE, Meissner N. 2015. Type I IFNs act upon hematopoietic progenitors to protect and maintain hematopoiesis during Pneumocystis lung infection in mice. J Immunol 195: 5347-5357. http://dx.doi.org/10.4049/jimmunol.1501553.
61. Gu H, Zou Y-R, Rajewsky K. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73: 1155-1164. http://dx.doi.org/10.1016/0092-8674(93)90644-6.
62. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
63. Richert LE, Harmsen AL, Rynda-Apple A, Wiley JA, Servid AE, Douglas T, Harmsen AG. 2013. Inducible bronchus-associated lymphoid tissue (iBALT) synergizes with local lymph nodes during antiviral CD4+ T cell responses. Lymphat Res Biol 11: 196-202. http://dx.doi.org/10.1089/lrb.2013.0015.
64. Morales-Nebreda L, Chi M, Lecuona E, Chandel NS, Dada LA, Ridge K, Soberanes S, Nigdelioglu R, Sznajder JI, Mutlu GM, Budinger GR, Radigan KA. 2014. Intratracheal administration of influenza virus is superior to intranasal administration as a model of acute lung injury. J Virol Methods 209: 116-120. http://dx.doi.org/10.1016/j.jviromet.2014.09.004.
65. Wiley JA, Cerwenka A, Harkema JR, Dutton RW, Harmsen AG. 2001. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol 158: 119-130. http://dx.doi.org/10.1016/S0002-9440(10)63950-8.
66. Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. 2006. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 26: 804-819. http://dx.doi.org/10.1089/jir.2006.26.804.
67. Qin L, Greenland JR, Moriya C, Cayabyab MJ, Letvin NL. 2007. Effects of type I interferons on the adjuvant properties of plasmid granulocytemacrophage colony-stimulating factor in vivo. J Virol 81: 10606-10613. http://dx.doi.org/10.1128/JVI.01000-07.